VBI Vaccines, Inc. – (NASDAQ:VBIV) dropped 4.9% during mid-day trading on Tuesday . The stock traded as low as $3.56 and last traded at $3.70, with a volume of 77,626 shares trading hands. The stock had previously closed at $3.89.

Separately, Ladenburg Thalmann initiated coverage on VBI Vaccines, Inc. – in a research note on Tuesday, July 26th. They issued a “buy” rating for the company.

The firm has a 50 day moving average of $3.74 and a 200 day moving average of $3.87. The firm’s market cap is $131.89 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/vbi-vaccines-inc-vbiv-stock-price-down-4-9.html

Institutional investors have recently made changes to their positions in the stock. BlackRock Fund Advisors raised its position in shares of VBI Vaccines, Inc. – by 1,701.6% in the second quarter. BlackRock Fund Advisors now owns 44,789 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 42,303 shares in the last quarter. Vanguard Group Inc. raised its position in shares of VBI Vaccines, Inc. – by 2,094.1% in the second quarter. Vanguard Group Inc. now owns 358,275 shares of the biopharmaceutical company’s stock valued at $1,415,000 after buying an additional 341,946 shares in the last quarter. Finally, Hudson Bay Capital Management LP acquired a new position in shares of VBI Vaccines, Inc. – during the first quarter valued at $2,338,000.

VBI Vaccines, Inc. – Company Profile

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

5 Day Chart for NASDAQ:VBIV

Receive News & Ratings for VBI Vaccines Inc. - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. - and related companies with MarketBeat.com's FREE daily email newsletter.